US FTC seeks more information from Teva, Cephalon on merger
This article was originally published in Scrip
Executive Summary
The US Federal Trade Commission has requested additional information from both Teva Pharmaceutical Industries and Cephalon regarding Teva's pending $6.8 billion acquisition of the Frazier, Pennsylvania firm.